Cue Biopharma develops immunotherapies that mimic natural immune signals to selectively activate tumor-specific T cells within patients' bodies, targeting only cancer cells. This approach enhances the effectiveness of cancer treatment while preserving the safety of the patient's immune system.
Funding
$12M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer immunotherapies often lack specificity, leading to systemic immune activation and off-target effects that can cause significant toxicity. Broad immune stimulation can also result in suboptimal T cell activation within the tumor microenvironment, limiting therapeutic efficacy.
Solution
Cue Biopharma is developing a novel class of biologics that selectively activate tumor-specific T cells directly within the patient's body. These immunotherapies mimic natural immune signals, or "Cues", to engage and stimulate the patient's own immune system to target and destroy cancer cells. By focusing the immune response on tumor cells, this approach aims to enhance treatment effectiveness while minimizing off-target toxicity and preserving the patient's overall immune health. The company's Immuno-STAT, Neo-STAT, and RDI-STAT platforms are designed to address various aspects of tumor immunology and optimize T cell activation for different cancer types.
Target Audience
The primary target audience includes patients with various types of cancer who may benefit from more targeted and effective immunotherapeutic approaches, as well as oncologists and researchers seeking to improve cancer treatment outcomes.
Features
- Immuno-STAT platform: Designed to activate and expand tumor-specific T cells by mimicking natural immune signals.
- Neo-STAT platform: Focuses on targeting neoantigens, unique markers present on cancer cells, to elicit a highly specific immune response.
- RDI-STAT platform: Aims to redirect and enhance the activity of immune cells within the tumor microenvironment.
- Selective T cell activation: Minimizes off-target effects and systemic toxicity associated with traditional immunotherapies.